A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.

Trial Details

NCT ID
NCT05592626
Phase
PHASE1 / PHASE2
Sponsor
Marengo Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • STAR0602
Locations (sample)
  • Sacramento, California, United States|38.58157,-121.4944
  • Celebration, Florida, United States|28.32529,-81.53313
  • Miami, Florida, United States|25.77427,-80.19366
  • Kansas City, Kansas, United States|39.11417,-94.62746
  • Bethesda, Maryland, United States|38.98067,-77.10026

Key Eligibility Criteria

  • Participants must have histologically confirmed solid tumors that are unresectable, locally advanced, or metastatic and for which standard curative…
  • For Phase 1, participants must have one of the following solid tumors:
  • High mutational burden (TMB-H)
  • Microsatellite Instability (MSI-H)/DNA mismatch repair (dMMR)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →